Oligomerization of p53 precedes its association with dynein and nuclear accumulation

Cell Cycle

Volumn 5, Issue 19, 2006, Pages 2253-2259

  Trostel, Shana Y ^a   Sackett, Dan L ^b   Fojo, Tito ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

Dynein; Microtubule transport; Microtubules; Nuclear localization; Oligomerization; p53; p53 tetramerization; Tubulin

Indexed keywords

DYNEIN ADENOSINE TRIPHOSPHATASE; PROTEIN P53;

ARTICLE; COLON POLYPOSIS; CONTROLLED STUDY; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; HUMAN; HUMAN CELL; OLIGOMERIZATION; PROTEIN ANALYSIS; PROTEIN LOCALIZATION;

EID: 33749614293     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.5.19.3291     Document Type: Article

References (41)

1. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997; 88:323-31.
2. Ko LJ, Prives C. p53: Puzzle and paradigm. Genes Dev 1996; 10:1054-1072.
3. Sengupta S, Harris CC. p53: Traffic cop at the crossroads of DNA repair and recombination. Nature 2005; 6:44-55.
4. Levine AJ, Momand J, Finlay CA. The p53 tumour suppressor gene. Nature 1991; 351:453-6.
5. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991; 253:49-53.
6. El-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998; 8:345-57.
7. Apella E, Anderson CW. Signaling to p53: Breaking the posttranslational modification code. Pathol Biol 2000; 48:227-45.
8. Downing KH, Nogales E. Tubulin structure: Insights into microtubule properties and functions. Curr Opin Struct Biol 1998; 8:785-91.
9. Jordan MA, Wilson L. Microtubules and actin filaments: Dynamic targets for cancer chemotherapy. Curr Opin Cell Biol 1998; 10:123-30.
10. Joshi HC. Microtubule dynamics in living cells. Curr Opin Cell Biol 1998; 10:35-44.
11. Goodson HV, Valetti C, Kreis TE. Motors and membrane traffic. Curr Opin Cell Biol 1997; 9:18-28.
12. Hirokawa N. Kinesin and dynein superfamily proteins and the mechanism of organelle transport. Science 1998; 279:519-26.
13. Giannakakou P, Sackett DL, Ward Y, Webster KR, Blagosklonny MV, Fojo T. p53 is associated with cellular microtubules and is transported to the nucleus by dynein. Nature Cell Biol 2000; 2:709-17.
14. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ, Kohn KW. Characterization of the p53 tumor suppressor pathway in cell lines of the national cancer institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997; 57:4285-300.
15. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 1995; 80:293-9.
16. El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. WAF1, a potential mediator of p53 tumor suppression. Cell 1993; 75:817-25.
17. Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild type p53 activity. EMBO J 1993; 12:461-8.
18. Chène P. The role of tetramerization in p53 function. Oncogene 2001; 20:2611-7.
19. Xanthoudakis S, Miao GG, Curran T. The redox and DNA-repair activities of Ref-1 are encoded by nonoverlapping domains. Proc Natl Acad Sci USA 1994; 91:23-7.
20. Hanson S, Kim E, Deppert W. Redox factor 1 (Ref-1) enhances specific DNA binding of p53 by promoting p53 tetramerization. Oncogene 2005; 24:1641-7.
21. Balczon R, Varden CE, Schroer TA. Role for microtubules in centrosome doubling in chinese hamster ovary cells. Cell Motil Cytoskeleton 1999; 42:60-72.
22. Donehower RC, Rowinsky EK, Grochow LB, Longnecker SM, Ettinger DS. Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep 1987; 71:1171-7.
23. Rowinsky EK, Donehower RC. The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapies. Pharmacol Ther 1991; 52:35-84.
24. Rowinsky EK. Paclitaxel pharmacology and other tumor types. Semin Oncol 1997; 24:S19-1-S19-12.
25. Arbuck SG, Christian MC, Fisherman JS, Cazenave LA, Sarosy G, Suffness M, Adams J, Canetta R, Cole KE, Friedman MA. Clinical development of Taxol. J Natl Cancer Inst Monogr 1993; 11-24.
26. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nature Rev Cancer 2004; 4:253-65.
27. Downing KH. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Annu Rev Cell Dev Biol 2000; 16:89-111.
28. Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ, Wahl GM. A leucine-rich nuclear export signal in the p53 tetramerization domain: Regulation of subcellular localization and p53 activity by NES masking. EMBO J 1999; 18:1660-72.
29. Shaulsky G, Goldfinger N, Ben-Ze'ev A, Rotter V. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol Cell Biol 1990; 10:6565-77.
30. Liang S, Hong D, Clarke MF. Cooperation of a single lysine mutation and a c-terminal domain in the cytoplasmic sequestration of the p53 protein. J Biol Chem 1998; 273:19817-21.
31. Liang S, Clarke MF. A bipartite nuclear localization signal is required for p53 nuclear import regulated by a carboxyl-terminal domain. J Biol Chem 1999; 274:32699-703.
32. Mateu MG, Fersht AR. Nine hydrophobic side chains are key determinants of the thermodynamic stability and oligomerization status of tumor suppressor p53 tetramerization domain. EMBO J 1998; 17:2748-58.
33. McCoy M, Stavridi ES, Waterman JL, Wieczorek AM, Opella SJ, Halazonetis TD. Hydrophobic side-chain size is a determinant of the three-dimensional structure of the p53 oligomerization domain. EMBO J 1997; 16:6230-6.
34. Johnson CR, Morin PE, Arrowsmith CH, Freire E. Thermodynamic analysis of the structural stability of the tetrameric oligomerization domain of p53 tumor suppressor. Biochemistry 1995; 34:5309-16.
35. Stürzbecher H, Brain R, Addison C, Rudge K, Remm M, Grimaldi M, Keenan E, Jenkins JR. A c-terminal a-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 1992; 7:1513-23.
36. DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC, Zambetti G, Kriwacki RW. A novel mechanism of tumorigenesis involving pH-dependent destabilization of a mutant p53 tetramer. Nature Struct Biol 2002; 9:12-6.
37. Friedman PN, Chen X, Bargonetti J, Prives C. The p53 protein is an unusually shaped tetramer that binds directly to DNA. Proc Natl Acad Sci USA 1993; 90:3319-23.
38. Görlich D, Kutay U. Transport between the cell nucleus and the cytoplasm. Annu Rev Cell Dev Biol 1999; 15:607-60.
39. Pratt WB, Galigniana MD, Harrell JM, DeFranco DB. Role of hsp90 and the hsp90-binding immunophilins in signalling protein movement. Cell Signal 2004; 16:857-72.
40. Galigniana MD, Harrell JM, O'Hagen HM, Ljungman M, Pratt WB. Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus. J Biol Chem 2004; 279:22483-9.
41. Lo KW, Kan H, Chan L, Xu W, Wang K, Wu Z, Sheng M, Zhang M. The 8-kDa dynein light chain binds to p53-binding protein 1 and mediates DNA damage-induced p53 nuclear accumulation. J Biol Chem 2005; 280:8172-9.